Floatz logo

xnw28012

Advanced Solid Tumors

Evopoint Biosciences Inc.Phase 1/2Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
59/ 100

Competitive context

1411 Active assets in the Advanced Solid Tumors cohort.

View all 50

Same molecule, other indications

xnw28012 is also rated in:

cervical cancerDormant
CC
Indicative ·
47 / 100
View asset →
exocrine pancreatic carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
ovarian cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →